$2.19
0.45% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Innate Pharma - ADR Stock price

$2.19
-0.04 1.79% 1M
+0.73 50.00% 6M
+0.35 19.02% YTD
-0.56 20.36% 1Y
-0.85 27.96% 3Y
-4.16 65.51% 5Y
-3.86 63.80% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.01 0.45%
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Key metrics

Market capitalization $207.27m
Enterprise Value $205.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.38
P/S ratio (TTM) P/S ratio 14.47
P/B ratio (TTM) P/B ratio 18.31
Revenue growth (TTM) Revenue growth -75.69%
Revenue (TTM) Revenue $14.32m
EBIT (operating result TTM) EBIT $-58.53m
Free Cash Flow (TTM) Free Cash Flow $-8.27m
Cash position $91.65m
EPS (TTM) EPS $-0.69
P/E forward 1.51
P/S forward 2.11
EV/Sales forward 2.10
Short interest 0.08%
Show more

Is Innate Pharma - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Innate Pharma - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Innate Pharma - ADR forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Innate Pharma - ADR forecast:

Buy
67%
Hold
33%

Financial data from Innate Pharma - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14 14
76% 76%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
14% 14%
150%
- Research and Development Expense 56 56
0% 0%
393%
-56 -56
554% 554%
-393%
- Depreciation and Amortization 2.26 2.26
61% 61%
16%
EBIT (Operating Income) EBIT -59 -59
307% 307%
-409%
Net Profit -56 -56
554% 554%
-392%

In millions USD.

Don't miss a Thing! We will send you all news about Innate Pharma - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innate Pharma - ADR Stock News

Neutral
Business Wire
6 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.
Neutral
Business Wire
10 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggres...
Neutral
Business Wire
10 days ago
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
More Innate Pharma - ADR News

Company Profile

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Head office France
CEO Jonathan Dickinson
Employees 181
Founded 1999
Website www.innate-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today